Latest Sartorius Stedim Bio (SDMHF) Headlines B
Post# of 3
Bioseparation Systems for Global Biopharmaceutical Markets: 2013 Report
M2 - Tue Dec 17, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b887q/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets: 2013 Report" report to their offering. Bioseparations systems can be categorized into three types: chromatography, membranes/filters and centrifuges. The demand for single use products is increasing and fueling growth of the global bioseparations market. New biosimilars are driving the increase in global biomanufacturing capacity. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. This report provides market revenue size and growth rates for North America, Europe, Asia-Pacific (Japan, South Korea, Singapore) and the emerging BRICs (Brazil, Russia, India, China). Single-use products, manufacturing capacity, applications of bioseparations in downstream processing, downstream processing bottlenecks and emerging bioseparations technologies are covered in detail. The report also analyzes the competitive landscape, including key players' strengths and weaknesses, opportunities, gaps and industry trends. Detailed tables and charts with sales forecasts and marketshare data are also included. Scope of the Report - Single use products - Manufacturing capacity - Applications of bioseparations in downstream processing - Downstream processing bottlenecks - Emerging bioseparations technologies - Manufacturing capacity by biopharmaceutical company, CMO and region Key Topics Covered: 1. Introduction 2. Overview 3. Biologics in the Development Phase 4. Bioseparations Products and Systems 5. The Biopharmaceutical Manufacturing Process 6. Bioseparation Processes Used for Biologics Manufacturing 7. Global Bioseparation Market Analysis 8. The Global Bioseparations Market by Region 9. Competitive Landscape 10. Industry Analysis 11. Single-Use Bioseparations Systems and Products 12. Chromatography for Bioseparations 13. Filters and Membranes Used for Bioseparations 14. Industrial Centrifuges for Downstream Processing 15. Company Profiles Companies Mentioned: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/8b...separation
Sartorius Stedim Biotech and BD Diagnostics Strengthen Cooperation in the Area of Microbiological Diagnostics
PR Newswire Europe - Wed Oct 16, 2:01AM CDT
-- Expansion of Product Portfolio for Microbiological Analyses in the Lab
Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
M2 - Tue Aug 13, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pq64s6/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets" report to their offering. 72 1024x768 Normal 0 false false false This new report, "Global Markets for Bioseparations for Biopharmaceutical Manufacturing," cites that the global market for bioseparations for biopharmaceutical manufacturing will grow to $6 billion by 2018. While North America and Europe will continue to account for a significant share of revenue, the emerging countries of China, India, Brazil and Russia are rapidly increasing share, growing at a CAGR of 22%. The demand for single use products is increasing and fueling growth of the global bioseparations market. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. The Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs, producing biosimilars for their own large populations and for Southeast Asia. bioseparations market. Membranes/filters will contribute $1.4 billion, followed by centrifuges ($400 million). The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report covers: Normal 0 false false false MicrosoftInternetExplorer4 The "Global Markets for Bioseparations for Biopharmaceutical Manufacturing" report examines companies manufacturing biopharmaceutical manufacturing equipment and supplies in the world. Companies covered include: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/pq...separation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IV Fluid Transfer Devices Report - Products, Players, Markets and Opportunities
M2 - Wed Jun 26, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fnpmtc/iv_fluid_transfer) has announced the addition of the "IV Fluid Transfer Devices Products, Players, Markets and Opportunities" report to their offering. Intravenous drug administration is one of the most common therapeutic procedures that patients in a hospital setting are likely to receive. Yet the lack of standardization among the various components, elements and steps that a caregiver must navigate to successfully execute a drug intravenously have - according to several recent studies - contributed to medication errors and risks to patient safety. IV drug administration was once provided to patients only in clinical settings. However, technology developments and a greater emphasis on cost containment over the last 30 years have prompted a shift to providing this therapy in alternate settings, including the home. Highlights: - Analyzes the global market for IV fluid transfer devices market segments, and assesses the probable market
ProMetic and Sartorius Stedim Biotech ("SSB") Join Forces to Promote Novel Turnkey Solution for Producing Plasma-Derived Therapeutics
Marketwire - Tue Apr 30, 4:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB") to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPS(TM) on a global basis.
Sartorius Stedim Biotech: Fact Sheet on New Reporting Format
Business Wire - Mon Apr 15, 1:32PM CDT
From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris IM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech's business figures for 2012 as well as its earnings guidance for 2013 according to these changes.
Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media
Business Wire - Wed Dec 19, 12:00AM CST
--Long-term collaboration, supply and distribution agreement with Swiss-based life science group Lonza